Screening patients to assess renal function before administering gadolinium chelates: Assessment of the Choyke questionnaire

American Journal of Roentgenology

Volumn 195, Issue 2, 2010, Pages 424-428

  Sena, Brena F ^a   Stern, Julia P ^a   Pandharipande, Pari V ^a   Klemm, Barbara ^a   Bulman, Julie ^a   Pedrosa, Ivan ^a   Rofsky, Neil M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Efficacy; Gadolinium chelates; MRI; Nephrogenic systemic fibrosis; Renal insufficiency; Screening

Indexed keywords

GADOLINIUM CHELATE; CHELATING AGENT; CONTRAST MEDIUM; GADOLINIUM;

ADULT; ANALYTIC METHOD; ARTICLE; BLOOD SAMPLING; ECONOMIC ASPECT; FEMALE; GLOMERULUS FILTRATION RATE; HIGH RISK PATIENT; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTPATIENT; PATIENT ASSESSMENT; PRIORITY JOURNAL; QUESTIONNAIRE; SCREENING TEST; SENSITIVITY AND SPECIFICITY; AGED; DIAGNOSTIC USE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; INCIDENCE; KIDNEY DISEASES; KIDNEY FUNCTION TEST; MASS SCREENING; MIDDLE AGED; PROCEDURES; REPRODUCIBILITY; RISK ASSESSMENT; RISK FACTOR; STATISTICS AND NUMERICAL DATA; UNITED STATES; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BOSTON; CHELATING AGENTS; CONTRAST MEDIA; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; GADOLINIUM; HUMANS; INCIDENCE; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; MAGNETIC RESONANCE IMAGING; MALE; MASS SCREENING; MIDDLE AGED; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 77955594952     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.09.3803     Document Type: Article

References (21)

1. Grobner T. Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant, 2006; 21:1104-1108
2. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006; 17:2359-2362 (Pubitemid 44300951)
3. Shellock FG, Spinazzi A. MRI safety update 2008. Part I. MRI contrast agents and nephrogenic systemic fibrosis. AJR 2008; 191:1129-1139
4. Perazella MA, Rodby RA. Gadolinium use in patients with kidney disease: a cause for concern. Semin Dial 2007; 20:179-185
5. United States Food and Drug Administration. FDA requests boxed warning for contrast agents used to improve MRI images. www.fda.gov./NewsEvents/ Newsroom/PressAnnouncements/2007/ucm108919.htm. Accessed December 15, 2009
6. U.S. Food and Drug Administration public health advisory: gadolinium-containing contrast agents for magnetic resonance imaging (MRI) - Omniscan, OptiMARK, Magnevist, ProHance, and MultiHance. www.fda.gov/Drugs/ DrugSafety/PublicHealthAdvisories/ucm053112.htm. Published June 8, 2006. Accessed March 24, 2010
7. Weinreb JC. Impact on hospital policy: Yale experience. J Am Coll Radiol 2008; 5:53-56
8. Juluru K, Vogel-Claussen J, Macura KJ, Kamel IR, Steever A, Bluemke DA. MR imaging in patients at risk for developing nephrogenic systemic fibrosis: protocols, practices, and imaging techniques to maximize patient safety. RadioGraphics 2009; 29:9-22
9. Choyke PL, Cady J, DePollar SL, Austin H. Determination of serum creatinine prior to iodinated contrast media: is it necessary in all patients? Tech Urol 1998; 4:65-69 (Pubitemid 28237617)
10. Tippins RB, Torres WE, Baumgartner BR, Baumgarten DA. Are screening serum creatinine levels necessary prior to outpatient CT examinations? Radiology 2000; 216:481-484
11. Olsen JC, Salomon B. Utility of the creatinine prior to intravenous contrast studies in the emergency department. J Emerg Med 1996; 14:543-546 (Pubitemid 26376535)
12. Lameire N, Adam A, Becker CR, et al. Baseline renal function screening. Am J Cardiol 2006; 98:21K-26K
13. Herts BR, Schneider E, Poggio ED, Obuchowski NA, Baker ME. Identifying outpatients with renal insufficiency before contrast-enhanced CT by using estimated glomerular filtration rates versus serum creatinine levels. Radiology 2008; 248:106-113
14. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation - Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130:461-470
15. Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003; 139:137-147
16. Center for Medicare and Medicaid Services Website. Clinical laboratory fee schedule and physician fee schedule. www.cms.hhs.gov/home/medicare.asp. Accessed March 24, 2010
17. Bridges MD, St. Amant BS, McNeil RB, Cernigliaro JG, Dwyer JP, Fitzpatrick PM. High-dose gadodiamide for catheter angiography and CT in patients with varying degrees of renal insufficiency: prevalence of subsequent nephrogenic systemic fibrosis and decline in renal function. AJR 2009; 192:1538-1543
18. Weinreb JC. Which study when? Is gadolinium-enhanced MR imaging safer than iodine-enhanced CT? Radiology 2008; 249:3-8
19. Reilly RF. Risk for nephrogenic systemic fibrosis with gadoteridol (ProHance) in patients who are on long-term hemodialysis. Clin J Am Soc Nephrol 2008; 3:747-751
20. Rofsky NM, Sherry AD, Lenkinski RE. Nephrogenic systemic fibrosis: a chemical perspective. Radiology 2008; 247:608-612
21. Kanal E, Broome DR, Martin DR, Thomsen HS. Response to the FDA's May 23, 2007, nephrogenic systemic fibrosis update. Radiology 2008; 246:11-14